Application of FUNDC1 in treating acute respiratory distress syndrome and belongs to technical field of biology
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
- Publication Date
- 2020-05-12
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the field of biotechnology, in particular to the application of FUNDC1 in the treatment of acute respiratory distress syndrome. Background technique
[0002] The etiology of acute respiratory distress syndrome (ARDS) is complex, and its pathogenesis has not been fully elucidated. Numerous studies have shown that the inflammatory response in the lung is the most important cause of ALI / ARDS. The activation of innate and adaptive immunity leads to a series of inflammatory responses, and the release of a large number of cytokines and inflammatory mediators leads to the aggravation of lung injury. The end result of this uncontrolled inflammatory response in the lung is damage to alveolar epithelial cells (AEC) and capillary endothelial cells, which in turn leads to alveolar hemorrhage, pulmonary edema formation, and hyaline membrane production.
[0003] Autophagy is a lysosome-dependent biological process for degrading intracellul...